(Photo Courtesy: www.headwaysolar.com)
The deal is said to be an all cash transaction worth $550 million.
The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in LTM June 2015.
Located in New York (NY), InvaGen was established in 2003, and focuses on development, manufacturing, marketing and distributing of generics on a wide range of therapeutic areas including cardiovascular, anti-infective, CNS, anti-inflammatory, anti-diabetic and anti-depressants.
Through this acquisition, Cipla will also gain InvaGen's 3 manufacturing units located in Long Island, NY.
The units boast of production capacity of 12 billion tablets and capsules per year.